Explore the Agenda
7:15 am Morning Check in & Coffee
7:55 am Chair’s Opening Remarks
Transforming Patient Care Through Understanding Disease Complexity & Heterogeneity
8:00 am Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
- Highlighting how locally bioactivated pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD
8:30 am Unlocking the Power of Clinical Phenotypes to Advance Precision Medicine Targets
- Highlighting stable, well-established features, such as ileal and colonic Crohn’s disease, that correlate with treatment outcomes and complication risk
- Demonstrating how clinical phenotypes could guide patient stratification in clinical trials, identify subpopulations most likely to respond, and optimize therapy selection
- Discussing why precision medicine approaches in IBD have lagged behind oncology, and how aligning research priorities with commercial feasibility can help advance targeted therapies
9:00 am Roundtable Discussion: Advancing Patient Outcomes by Addressing Heterogeneity in Crohn’s Disease & Ulcerative Colitis
- Clinical complexity of Crohn’s Disease including fibrostenosis, fistula formation, and inflammation independent complications
- Limitations of current therapies that control inflammation but fail to resolve fibrosis or tissue damage
- Exploring unmet needs and future therapeutics from a clinicians perspective
9:45 am Morning Break & Networking
Unlocking Drug Discovery Insights Through Omics and AI in Complex Gut Disease Models
10:45 am Innovative Multiomics Strategies to Accelerate Drug Development and Decode Disease Mechanisms
- Discover how molecular signatures across disease phenotypes inform drug response and resistance, with applications beyond primary indications
- Learn how tissue mass spectrometry and long-read sequencing offer deeper insights into disease biology and overcome limitations of traditional short-read approaches
- Explore innovative multiomics frameworks that reveal hidden patterns in unstable and fibrotic disease states, enabling more precise therapeutic development
11:15 am Harnessing Multiomics and Machine Learning to Overcome Metadata Challenges and Build Predictive Biomarker Signatures
- Address logistical and analytical challenges in metadata capture to ensure robust, reproducible linkage between omics data and clinical outcomes
- Discuss how multiomic integration can reflect IBD’s molecular complexity and drive more accurate biomarker discover
- Learn how machine learning approaches can integrate multiomic datasets to identify composite
11:45 am Lunch Break & Networking
Transforming Clinical Trial Formation Through Biomarker Innovation, Advanced Imaging & Mechanism-Based Endpoints
12:45 pm Redefining Success in IBD Clinical Trials by Investigating Mechanism of Therapeutic Response/Non-Response & Driving Innovation
- Highlight the limitations of existing treatments in achieving full remission
- Show how residual disease activity leads to complications like fibrosis, fistulas, and surgery
- Explore how precision endpoints and biomarker-guided trials can improve therapeutic targeting
1:15 pm Integrating Imaging-Based Biomarkers to Advance Precision in IBD Clinical Trials
- Maximizing the value of endoscopy by driving consistency in centralized reads
- Opportunities and challenges with deploying MRI based biomarkers in global clinical trials
- Emerging opportunities for AI tools to automate and accelerate central reviews
1:45 pm Using Blood-Based Epigenetic Signatures to Personalize First-Line Biologic Therapy in Crohn’s Disease
- Investigating a scalable, blood-derived DNA methylation panel designed to guide first-line biologic selection at diagnosis, aiming to move beyond today’s trial-and-error paradigm and reduce early complications linked to ineffective therapy
- Leveraging a validated epigenetic algorithm undergoing testing in the OMICRON clinical trial to improve therapeutic success rates
- Establishing a blueprint for cross-disease precision medicine, with methylation markers and machine-learning pipelines engineered for translation